{'fraction_non_alphanumeric': 0.022641509433962263, 'fraction_numerical': 0.018867924528301886, 'mean_word_length': 5.03030303030303, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identification of Novel Polo‐like Kinase 1 Inhibitors by a Hybrid Virtual Screening

Polo‐like kinase 1 is an important and attractive oncological target that plays a key role in mitosis and cytokinesis. A combined pharmacophore‐ and docking‐based virtual screening was performed to identify novel polo‐like kinase 1 inhibitors. A total of 34 hit compounds were selected and tested in vitro, and some compounds showed inhibition of polo‐like kinase 1 and human tumor cell growth. The most potent compound (66) inhibited polo‐like kinase 1 with an IC50 value of 6.99 μm. The docked binding models of two hit compounds were discussed in detail. These compounds contained novel chemical scaffolds and may be used as foundations for the development of novel classes of polo‐like kinase 1 inhibitors.